HIGHLIGHTS
- What: While current immunosuppressive therapies have significantly improved overall survival for patients with AAV, there remains a subset of patients who will prove refractory to these treatments, such as our patient described in the case above.
- Who: Report et al. from the System, Newark, USA have published the article: Review began 05/02/2024 Review ended 05/08/2024 Published 05/15/2024 © Copyright, in the Journal: (JOURNAL) of April/19,/2024
- Future: Studies are needed to help determine which patients would benefit from the early initiation of novel therapies such as avacopan . . .

If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.